We are dedicated to developing innovative microbial therapies that have the potential to significantly improve the health and well-being of the patients we serve. To meet this goal, we conduct clinical trials to determine the safety and efficacy of the new therapies we develop.
Currently, the following Finch-sponsored trials are enrolling participants:
PRISM 3: A CLINICAL trial FOR RECURRENT C. Difficile Infection
PRISM 3 is a Phase 2 clinical trial evaluating the safety and effectiveness of using CP101, a Full-Spectrum Microbiota oral therapy, compared to a placebo, to prevent recurrence of Clostridium difficile infection (CDI). PRISM 3 is currently enrolling patients at clinical sites throughout the U.S.